The leading limitation of our review was the inability to check a PD-1/PD-L1 inhibitor together with S and S+R as a result of unavailability of the rat cross reactive antibody. Having said that, we did clearly show PD-L1 upregulation on- or write-up- treatment with S and S+R that's why substantially addressing this limitation.*Please Be aware that